Monopar Therapeutics (MNPR) Operating Leases (2022 - 2025)

Monopar Therapeutics (MNPR) reported Operating Leases of $154920.0 for Q4 2025, up 118.56% sequentially from $70881.0 in Q3 2025.

Monopar Therapeutics (MNPR) Operating Leases (2022 - 2025) Analysis & Trends

Monopar Therapeutics (MNPR) has 2 years of Operating Leases data on file, last reported at $154920.0 in Q4 2025.

For the quarter ending Q4 2025, Operating Leases changed N/A year-over-year to $154920.0; the trailing twelve-month figure through Dec 2025 stood at $154920.0 (changed N/A YoY), and the FY2025 full-year result was $154920.0, changed N/A from the prior year.
Operating Leases grew to $154920.0 in Q4 2025, from $70881.0 in the prior quarter.
In the past five years, Operating Leases ranged from a high of $154920.0 in Q4 2025 to a low of $8408.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Monopar Therapeutics	800.03 Mn	738.20 Mn	-

Download Data